IDH1-mutant Cholangiocarcinoma
Oncology
Prevalence
2.5 / 100K
Incidence
1.3 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| Ivosidenib | ENANTA PHARMACEUTICALS INC (ENTA) |
Frequently asked questions
How many drugs are in development for IDH1-mutant Cholangiocarcinoma?
BioSniper tracks 1 drug in development for IDH1-mutant Cholangiocarcinoma across 1 company.
How many clinical trials target IDH1-mutant Cholangiocarcinoma?
There are 1 clinical trial targeting IDH1-mutant Cholangiocarcinoma tracked by BioSniper.
What is the prevalence of IDH1-mutant Cholangiocarcinoma?
The estimated prevalence of IDH1-mutant Cholangiocarcinoma is approximately 2.5 per 100,000 population.
Deep-dive into IDH1-mutant Cholangiocarcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis